Alumis Inc. Common Stock
$24.13
The Read: Alumis’s stock showed muted or slightly negative reactions around initial positive Phase 3 envudeucitinib data and NDA plans in March 2026, but surged about 19% after late-breaking robust clinical results at the AAD meeting in Q2 2026 overcame earlier liquidity concerns.
Price
Overlays
Panel
ALMS
Hover to view data
No Data